Current therapies target a limited number of mutations. Increasing use of liquid biopsies and next generation sequencing is revealing a large number of oncogenic alterations for which no therapies exist. Our MasterKey approach targets broad families of oncogenic mutations, with the potential to benefit large patient populations with limited treatment options.

We have generated two clinical-stage MasterKey drug candidates: BDTX-1535 for patients with EGFR-mutant NSCLC or GBM, and BDTX-4933 for patients with KRAS-mutant NSCLC or RAF/RAS-mutant tumors.